Search research articles
Contact Us
Filters
Showing results (81-90 of 425) with videos related to
Page
of 43
Sort By:
Expert Opinion on Pharmacotherapy
|
February 16, 2005
Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia
Peter P Toth, Michael H Davidson
JACC. Advances
|
June 28, 2024
Coronary Atherosclerosis: Causes, Consequences, and the Passage of Time
Peter P Toth, Allan D Sniderman
Current Drug Targets. Cardiovascular & Haematological Disorders
|
March 1, 2006
Cholesterol absorption blockade with ezetimibe
Peter P Toth, Michael H Davidson
The American Journal of Cardiology
|
December 6, 2007
High-density lipoprotein metabolism: potential therapeutic targets
Michael H Davidson, Peter P Toth
The Journal of Family Practice
|
August 9, 2008
High-dose statin therapy: benefits and safety in aggressive lipid lowering
Peter P Toth, Michael H Davidson
Progress in Cardiovascular Diseases
|
December 9, 2004
Comparative effects of lipid-lowering therapies
Michael H Davidson, Peter P Toth
Current Opinion in Cardiology
|
June 26, 2004
Therapeutic interventions targeted at the augmentation of reverse cholesterol transport
Peter P Toth, Michael H Davidson
Obesity (Silver Spring, Md.)
|
January 25, 2019
Trends in Lipids, Obesity, Metabolic Syndrome, and Diabetes Mellitus in the United States: An NHANES Analysis (2003-2004 to 2013-2014)
Michael K Palmer, Peter P Toth
European Cardiology
|
March 18, 2020
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Alberto J Lorenzatti, Peter P Toth
Journal of Clinical Lipidology
|
February 5, 2011
Implications of recent statin trials for primary care practice
Peter P Toth, Chris J Cadman
Page
of 43
Search research articles
Search
Showing results (81-90 of 425) with videos related to
Sort By:
Page
of 43
Expert Opinion on Pharmacotherapy
|
February 16, 2005
Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia
Peter P Toth, Michael H Davidson
JACC. Advances
|
June 28, 2024
Coronary Atherosclerosis: Causes, Consequences, and the Passage of Time
Peter P Toth, Allan D Sniderman
Current Drug Targets. Cardiovascular & Haematological Disorders
|
March 1, 2006
Cholesterol absorption blockade with ezetimibe
Peter P Toth, Michael H Davidson
The American Journal of Cardiology
|
December 6, 2007
High-density lipoprotein metabolism: potential therapeutic targets
Michael H Davidson, Peter P Toth
The Journal of Family Practice
|
August 9, 2008
High-dose statin therapy: benefits and safety in aggressive lipid lowering
Peter P Toth, Michael H Davidson
Progress in Cardiovascular Diseases
|
December 9, 2004
Comparative effects of lipid-lowering therapies
Michael H Davidson, Peter P Toth
Current Opinion in Cardiology
|
June 26, 2004
Therapeutic interventions targeted at the augmentation of reverse cholesterol transport
Peter P Toth, Michael H Davidson
Obesity (Silver Spring, Md.)
|
January 25, 2019
Trends in Lipids, Obesity, Metabolic Syndrome, and Diabetes Mellitus in the United States: An NHANES Analysis (2003-2004 to 2013-2014)
Michael K Palmer, Peter P Toth
European Cardiology
|
March 18, 2020
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Alberto J Lorenzatti, Peter P Toth
Journal of Clinical Lipidology
|
February 5, 2011
Implications of recent statin trials for primary care practice
Peter P Toth, Chris J Cadman
Page
of 43